Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants

Bone Marrow Transplantation

Volumn 21, Issue 9, 1998, Pages 923-926

  Koya, R ^a   Andersen, J ^b   Fernandez, H ^a   Goodman, M ^a   Spector, N ^a   Smith, R ^a   Hanlon, J ^a   Cassileth, P A ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Autologous stem cell transplant; Infections; Neutropenic fever; Vancomycin

Indexed keywords

ANTINEOPLASTIC AGENT; QUINOLONE; VANCOMYCIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD CULTURE; COST CONTROL; FEMALE; FEVER; GRAM STAINING; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0031953003     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701201     Document Type: Article

References (14)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
2. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 1993; 328: 1323-1332.
3. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986; 80 (Suppl. 5C): 13-20.
4. Klastersky J. Fiebrile neutropenia. Curr Opin Oncol 1993; 5: 625-632.
5. Groeger JS, Lucas AB, Thaler HT et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119: 1168-1174.
6. Ramphal R, Bolger M, Oblon D et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36: 1062-1067.
7. Gibson J, Johnson L, Snowdon L et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomized trial. Int J Hematol 1993; 58: 63-72.
8. Freifeld A, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165-176.
9. Karp JE, Dick JD, Angelopulos C et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986; 81: 237-242.
10. Giamarellou H. Empiric therapy for infections in the febrile, neutropenic compromised host. Med Clin N Amer 1995; 79: 559-580.
11. Gilbert C, Meisenberg B, Vredenburgh J et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12: 1005-1011.
12. Rubin M, Hathorn JW, Marshall D et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988; 108: 30-35.
13. Shenep JL, Hughes WT, Roberson PK et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. New Engl J Med 1988; 319: 1053-1058.
14. Anonymous. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958.